ArticleBiomaterials science2019
Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis.
Article in Biomaterials science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 90 citations in OpenAlex.
- Selective elimination of mast cells via Siglec-6-targeted nanodelivery of drug payload.The Journal of allergy and clinical immunology · 2026Article
- PEG-lipid shedding and biodistribution are shaped by nanocarrier morphology and lipid chemistry.Cell biomaterials · 2026Article
- Filomicelle-Embedded Composite Hydrogels for Localized Gelation Within the Anterior Chamber of the Eye.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Neutrophil Extracellular Traps: Potential Therapeutic Targets of Traditional Chinese Medicine and Natural Products for Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Emerging nanotechnological strategies for delivering bioactive components from botanical drugs and traditional Chinese medicine in atherosclerosis therapy: from formulation to mechanism.Frontiers in pharmacology · 2026Review
- Phytochemicals and nanoformulation strategies for rheumatoid arthritis: mechanistic insights, therapeutic advances, and translational challenges.Inflammopharmacology · 2026Review
- Nanodelivery of Bioactive Natural Products: A Targeted Therapeutic Breakthrough for Atherosclerosis.Pharmaceutics · 2025Review
- Platelet Membrane Biomimetic Chemiluminescent Nanoparticles for Targeted Therapy of Atherosclerosis.ACS applied materials & interfaces · 2025Article
- Bioinformatics-Driven Engineering of ROS-Responsive Dextran-ACS omega · 2025Article
- Application of Nanomaterials in Early Imaging and Advanced Treatment of Atherosclerosis.Chemical & biomedical imaging · 2025Review
- The role of celastrol in inflammation and diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- From Physicochemical Constraints to Clinical Prospects of Celastrol: Challenges and Nano Delivery Strategies.International journal of nanomedicine · 2025Review
- Recent Advances in Nanozymes for the Treatment of Atherosclerosis.International journal of nanomedicine · 2025Review
- Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer.Cancer cell international · 2024Article
- Precise modulation and use of reactive oxygen species for immunotherapy.Science advances · 2024Review
- Review
- Atherosclerosis: The Involvement of Immunity, Cytokines and Cells in Pathogenesis, and Potential Novel Therapeutics.Aging and disease · 2023Review
- Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.Drug delivery and translational research · 2023Review
- Celastrol-loaded biomimetic nanodrug ameliorates APAP-induced liver injury through modulating macrophage polarization.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Plant-Based Antioxidants for Prevention and Treatment of Neurodegenerative Diseases: Phytotherapeutic Potential ofAntioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
In this work, the hydrophobic small molecule NF-κB inhibitor celastrol was loaded into poly(ethylene glycol)-b-poly(propylene sulfide) (PEG-b-PPS) micelles. PEG-b-PPS micelles demonstrated high loading efficiency, low polydispersity, and no morphological changes upon loading with celastrol. Encapsulation of celastrol within these nanocarriers significantly reduced cytotoxicity compared to free celastrol, while simultaneously expanding the lower concentration range for effective inhibition of NF-κB signaling by nearly 50 000-fold. Furthermore, celastrol-loaded micelles successfully reduced TNF-α secretion after LPS stimulation of RAW 264.7 cells and reduced the number of neutrophils and inflammatory monocytes within atherosclerotic plaques of ldlr-/- mice. This reduction in inflammatory cells was matched by a reduction in plaque area, suggesting that celastrol-loaded nanocarriers may serve as an anti-inflammatory treatment for atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.